{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:38:40Z","timestamp":1771000720702,"version":"3.50.1"},"reference-count":49,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,8,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Bruton tyrosine kinase (Btk) has a well-defined role in B-cell development, whereas its expression in osteoclasts (OCs) further suggests a role in osteoclastogenesis. Here we investigated effects of PCI-32765, an oral and selective Btk inhibitor, on osteoclastogenesis as well as on multiple myeloma (MM) growth within the BM microenvironment. PCI-32765 blocked RANKL\/M-CSF\u2013induced phosphorylation of Btk and downstream PLC-\u03b32 in OCs, resulting in diminished TRAP5b (ED50 = 17nM) and bone resorption activity. PCI-32765 also inhibited secretion of multiple cytokines and chemokines from OC and BM stromal cell cultures from both normal donors (ED50 = 0.5nM) and MM patients. It decreased SDF-1\u2013induced migration of MM cells, and down-regulated MIP1-\u03b1\/CCL3 in MM cells. It also blocked MM cell growth and survival triggered by IL-6 or coculture with BM stromal cells or OCs in vitro. Importantly, PCI-32765 treatment significantly inhibits in vivo MM cell growth (P &lt; .03) and MM cell\u2013induced osteolysis of implanted human bone chips in SCID mice. Moreover, PCI-32765 prevents in vitro colony formation by stem-like cells from MM patients. Together, these results delineate functional sequelae of Btk activation mediating osteolysis and growth of MM cells, supporting evaluation of PCI-32765 as a novel therapeutic in MM.<\/jats:p>","DOI":"10.1182\/blood-2011-12-396853","type":"journal-article","created":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T05:49:44Z","timestamp":1339480184000},"page":"1877-1887","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":144,"title":["Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma"],"prefix":"10.1182","volume":"120","author":[{"given":"Yu-Tzu","family":"Tai","sequence":"first","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betty Y.","family":"Chang","sequence":"additional","affiliation":[{"name":"Pharmacyclics Inc, Sunnyvale, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun-Young","family":"Kong","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"},{"name":"Research Institute and Hospital, National Cancer Center, Goyang, Korea;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariateresa","family":"Fulciniti","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang","family":"Yang","sequence":"additional","affiliation":[{"name":"Bing Center for Waldenstr\u00f6m's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolanda","family":"Calle","sequence":"additional","affiliation":[{"name":"Department of Haematological Medicine, King's College London, London, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiguo","family":"Hu","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhong","family":"Lin","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Jun","family":"Zhao","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Cagnetta","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Cea","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Sellitto","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike Y.","family":"Zhong","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuju","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chirag","family":"Acharya","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel R.","family":"Carrasco","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"},{"name":"Department of Pathology, Brigham and Women's Hospital, Boston, MA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph J.","family":"Buggy","sequence":"additional","affiliation":[{"name":"Pharmacyclics Inc, Sunnyvale, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Elias","sequence":"additional","affiliation":[{"name":"Pharmacyclics Inc, Sunnyvale, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven P.","family":"Treon","sequence":"additional","affiliation":[{"name":"Bing Center for Waldenstr\u00f6m's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Matsui","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Richardson","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"},{"name":"Boston Veterans Administration Healthcare System, West Roxbury, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"1","key":"2019111811542416300_B1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1053\/j.seminhematol.2010.11.001","article-title":"Bone disease from monoclonal gammopathy of undetermined significance to multiple myeloma: pathogenesis, interventions, and future opportunities.","volume":"48","author":"Minter","year":"2011","journal-title":"Semin Hematol"},{"issue":"6","key":"2019111811542416300_B2","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1158\/1078-0432.CCR-10-1804","article-title":"Advances in the biology and treatment of bone disease in multiple myeloma.","volume":"17","author":"Raje","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2019111811542416300_B3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/hmg\/3.1.161","article-title":"Mutation analysis of the Bruton's tyrosine kinase gene in X-linked agammaglobulinemia: identification of a mutation which affects the same codon as is altered in immunodeficient xid mice.","volume":"3","author":"de Weers","year":"1994","journal-title":"Hum Mol Genet"},{"issue":"49","key":"2019111811542416300_B4","doi-asserted-by":"crossref","first-page":"5651","DOI":"10.1038\/sj.onc.1203958","article-title":"Signaling network of the Btk family kinases.","volume":"19","author":"Qiu","year":"2000","journal-title":"Oncogene"},{"issue":"5","key":"2019111811542416300_B5","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1086\/301828","article-title":"Mutations in btk in patients with presumed X-linked agammaglobulinemia.","volume":"62","author":"Conley","year":"1998","journal-title":"Am J Hum Genet"},{"key":"2019111811542416300_B6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1196\/annals.1358.014","article-title":"Human B cell tolerance and its failure in rheumatoid arthritis.","volume":"1062","author":"Samuels","year":"2005","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"2019111811542416300_B7","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1615\/CritRevImmunol.v29.i4.30","article-title":"The role of Tec family kinases in mononuclear phagocytes.","volume":"29","author":"Koprulu","year":"2009","journal-title":"Crit Rev Immunol"},{"issue":"1","key":"2019111811542416300_B8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nchembio.481","article-title":"Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.","volume":"7","author":"Di Paolo","year":"2011","journal-title":"Nat Chem Biol"},{"issue":"29","key":"2019111811542416300_B9","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2019111811542416300_B10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/nchembio.502","article-title":"Drug discovery: new Btk inhibitor holds promise.","volume":"7","author":"Hendriks","year":"2011","journal-title":"Nat Chem Biol"},{"issue":"1","key":"2019111811542416300_B11","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1124\/jpet.111.181545","article-title":"Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic\/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy.","volume":"338","author":"Liu","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"2019111811542416300_B12","doi-asserted-by":"crossref","first-page":"R115","DOI":"10.1186\/ar3400","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells.","volume":"13","author":"Chang","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"2019111811542416300_B13","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1053\/j.seminhematol.2011.05.001","article-title":"Molecular targeted approaches in mantle cell lymphoma.","volume":"48","author":"Weniger","year":"2011","journal-title":"Semin Hematol"},{"issue":"23","key":"2019111811542416300_B14","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2019111811542416300_B15","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.cell.2007.12.037","article-title":"Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals.","volume":"132","author":"Shinohara","year":"2008","journal-title":"Cell"},{"issue":"17","key":"2019111811542416300_B16","doi-asserted-by":"crossref","first-page":"11526","DOI":"10.1074\/jbc.M708935200","article-title":"The tec family tyrosine kinase Btk regulates RANKL-induced osteoclast maturation.","volume":"283","author":"Lee","year":"2008","journal-title":"J Biol Chem"},{"issue":"5","key":"2019111811542416300_B17","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1182\/blood-2007-03-081240","article-title":"Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.","volume":"110","author":"Tai","year":"2007","journal-title":"Blood"},{"issue":"4","key":"2019111811542416300_B18","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"issue":"13","key":"2019111811542416300_B19","doi-asserted-by":"crossref","first-page":"6675","DOI":"10.1158\/0008-5472.CAN-06-0190","article-title":"Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.","volume":"66","author":"Tai","year":"2006","journal-title":"Cancer Res"},{"issue":"4","key":"2019111811542416300_B20","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2141.2010.08127.x","article-title":"Blockade of the MEK\/ERK signalling cascade by AS703026, a novel selective MEK1\/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo.","volume":"149","author":"Kim","year":"2010","journal-title":"Br J Haematol"},{"issue":"18","key":"2019111811542416300_B21","first-page":"5850","article-title":"Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3\u2032-kinase\/AKT signaling.","volume":"63","author":"Tai","year":"2003","journal-title":"Cancer Res"},{"issue":"1","key":"2019111811542416300_B22","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.immuni.2006.11.012","article-title":"Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing.","volume":"26","author":"de Gorter","year":"2007","journal-title":"Immunity"},{"issue":"12","key":"2019111811542416300_B23","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1182\/blood-2004-03-0963","article-title":"Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells.","volume":"104","author":"Tassone","year":"2004","journal-title":"Blood"},{"issue":"19","key":"2019111811542416300_B24","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1158\/1078-0432.CCR-07-0753","article-title":"Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model.","volume":"13","author":"Neri","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2019111811542416300_B25","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2003-09-3064","article-title":"Characterization of clonogenic multiple myeloma cells.","volume":"103","author":"Matsui","year":"2004","journal-title":"Blood"},{"issue":"9","key":"2019111811542416300_B26","doi-asserted-by":"crossref","first-page":"e12487","DOI":"10.1371\/journal.pone.0012487","article-title":"Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms.","volume":"5","author":"Brennan","year":"2010","journal-title":"PLoS One"},{"issue":"3","key":"2019111811542416300_B27","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2004-11-4512","article-title":"The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature.","volume":"106","author":"Moreaux","year":"2005","journal-title":"Blood"},{"issue":"11","key":"2019111811542416300_B28","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1073\/pnas.0911929107","article-title":"Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease.","volume":"107","author":"Vallet","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2019111811542416300_B29","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1359\/jbmr.2000.15.7.1337","article-title":"Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption.","volume":"15","author":"Halleen","year":"2000","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2019111811542416300_B30","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1359\/jbmr.090810","article-title":"Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure.","volume":"25","author":"Body","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2019111811542416300_B31","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/sj.onc.1205205","article-title":"Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays.","volume":"21","author":"Chauhan","year":"2002","journal-title":"Oncogene"},{"issue":"7","key":"2019111811542416300_B32","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1182\/blood-2006-07-035857","article-title":"Mechanisms of regulation of CXCR4\/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.","volume":"109","author":"Alsayed","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2019111811542416300_B33","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood-2008-11-191577","article-title":"Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma.","volume":"114","author":"Fulciniti","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2019111811542416300_B34","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s00774-008-0012-z","article-title":"Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production.","volume":"27","author":"Abe","year":"2009","journal-title":"J Bone Miner Metab"},{"issue":"10","key":"2019111811542416300_B35","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1182\/blood-2007-05-093294","article-title":"MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.","volume":"110","author":"Vallet","year":"2007","journal-title":"Blood"},{"key":"2019111811542416300_B36","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1196\/annals.1346.035","article-title":"Bone destruction in multiple myeloma.","volume":"1068","author":"Matsumoto","year":"2006","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"2019111811542416300_B37","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1158\/0008-5472.CAN-04-1687","article-title":"Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients.","volume":"65","author":"Zannettino","year":"2005","journal-title":"Cancer Res"},{"issue":"7","key":"2019111811542416300_B38","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1359\/jbmr.090210","article-title":"Targeted disruption of the CXCL12\/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss.","volume":"24","author":"Diamond","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2019111811542416300_B39","doi-asserted-by":"crossref","first-page":"e9870","DOI":"10.1371\/journal.pone.0009870","article-title":"Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth.","volume":"5","author":"Takeuchi","year":"2010","journal-title":"PLoS One"},{"key":"2019111811542416300_B40","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1471-2407-9-83","article-title":"APRIL is overexpressed in cancer: link with tumor progression.","volume":"9","author":"Moreaux","year":"2009","journal-title":"BMC Cancer"},{"issue":"3","key":"2019111811542416300_B41","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1182\/blood-2010-01-264424","article-title":"APRIL promotes cell-cycle progression in primary multiple myeloma cells: influence of D-type cyclin group and translocation status.","volume":"117","author":"Quinn","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2019111811542416300_B42","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2009.08.019","article-title":"Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.","volume":"16","author":"Chauhan","year":"2009","journal-title":"Cancer Cell"},{"issue":"5","key":"2019111811542416300_B43","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.leukres.2006.06.012","article-title":"Cytokine and chemokine profiles in multiple myeloma: significance of stromal interaction and correlation of IL-8 production with disease progression.","volume":"31","author":"Kline","year":"2007","journal-title":"Leuk Res"},{"issue":"13","key":"2019111811542416300_B44","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1182\/blood-2007-02-074617","article-title":"The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angiogenesis.","volume":"110","author":"Colla","year":"2007","journal-title":"Blood"},{"issue":"6","key":"2019111811542416300_B45","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrrheum.2009.87","article-title":"Giant osteoclasts after long-term bisphosphonate therapy: diagnostic challenges.","volume":"5","author":"Jain","year":"2009","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"2019111811542416300_B46","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1056\/NEJMoa0802633","article-title":"Giant osteoclast formation and long-term oral bisphosphonate therapy.","volume":"360","author":"Weinstein","year":"2009","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111811542416300_B47","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1182\/blood-2003-04-1259","article-title":"WASp deficiency in mice results in failure to form osteoclast sealing zones and defects in bone resorption.","volume":"103","author":"Calle","year":"2004","journal-title":"Blood"},{"issue":"1","key":"2019111811542416300_B48","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/jbmr.210","article-title":"Elevated cytokine production restores bone resorption by human Btk-deficient osteoclasts.","volume":"26","author":"Danks","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2019111811542416300_B49","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1182\/blood.V85.3.627.bloodjournal853627","article-title":"Association and activation of Btk and Tec tyrosine kinases by gp130, a signal transducer of the interleukin-6 family of cytokines.","volume":"85","author":"Matsuda","year":"1995","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/9\/1877\/1363687\/zh803512001877.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/9\/1877\/1363687\/zh803512001877.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T16:59:52Z","timestamp":1574096392000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/9\/1877\/30927\/Bruton-tyrosine-kinase-inhibition-is-a-novel"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,30]]},"references-count":49,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,8,30]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-12-396853","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,30]]}}}